Paranasal Sinus Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major paranasal sinus diseases markets are expected to exhibit a CAGR of 4.3% during 2024-2034.
The paranasal sinus diseases market has been comprehensively analyzed in IMARC's new report titled "Paranasal Sinus Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Paranasal sinus diseases refer to various medical conditions that affect the paranasal sinuses, which are a group of air-filled cavities located within the bones surrounding the nose. These sinuses play a crucial role in producing mucus, which helps to humidify and filter the air we breathe. However, when the sinuses become inflamed or infected, they can lead to multiple health issues, like brain abscesses. Some common symptoms of the ailments include difficulty in breathing, a dull, aching sensation or pressure around the eyes, forehead, and cheeks, headache, excess mucus production, runny or stuffy nose, facial tenderness, loss of smell, altered sense of taste, cough, fatigue, fever, etc. The diagnosis of these diseases typically involves a combination of medical history assessment, clinical feature evaluation, and physical examination. The healthcare provider will also perform an endoscopy, in which a flexible tube with a light and camera may be inserted into the nasal passages to visualize the sinuses directly and identify any abnormalities. Numerous imaging techniques, like magnetic resonance imaging, computed tomography scans, X-rays, etc., are further utilized to detect the underlying cause of the conditions.
The rising cases of bacterial, viral, or fungal infections, which can result in inflammation and swelling of the nasal passage, are primarily driving the paranasal sinus diseases market. In addition to this, the increasing prevalence of anatomical abnormalities that affect the production of mucus, leading to thickened secretions in the respiratory system, is also creating a positive outlook for the market. Moreover, the widespread adoption of nasal corticosteroid sprays, since they help to reduce inflammation in the nasal passages and sinuses, as well as relieve congestion and symptoms in patients, is further bolstering the market growth. Apart from this, the inflating application of immunotherapy that desensitize the immune system to specific allergens and minimize the severity of allergic reactions is acting as another significant growth-inducing factor. Additionally, the emerging popularity of functional endoscopic sinus surgery, owing to its numerous advantages, such as minimal invasiveness, faster recovery, and fewer complications compared to traditional open procedures, is expected to drive the paranasal sinus diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the paranasal sinus diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for paranasal sinus diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the paranasal sinus diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the paranasal sinus diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the paranasal sinus diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current paranasal sinus diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the paranasal sinus diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the paranasal sinus diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the paranasal sinus diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with paranasal sinus diseases across the seven major markets?
What is the size of the paranasal sinus diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of paranasal sinus diseases?
What will be the growth rate of patients across the seven major markets?
Paranasal Sinus Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for paranasal sinus diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the paranasal sinus diseases market?
What are the key regulatory events related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by status related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by phase related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by route of administration related to the paranasal sinus diseases market?
The paranasal sinus diseases market has been comprehensively analyzed in IMARC's new report titled "Paranasal Sinus Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Paranasal sinus diseases refer to various medical conditions that affect the paranasal sinuses, which are a group of air-filled cavities located within the bones surrounding the nose. These sinuses play a crucial role in producing mucus, which helps to humidify and filter the air we breathe. However, when the sinuses become inflamed or infected, they can lead to multiple health issues, like brain abscesses. Some common symptoms of the ailments include difficulty in breathing, a dull, aching sensation or pressure around the eyes, forehead, and cheeks, headache, excess mucus production, runny or stuffy nose, facial tenderness, loss of smell, altered sense of taste, cough, fatigue, fever, etc. The diagnosis of these diseases typically involves a combination of medical history assessment, clinical feature evaluation, and physical examination. The healthcare provider will also perform an endoscopy, in which a flexible tube with a light and camera may be inserted into the nasal passages to visualize the sinuses directly and identify any abnormalities. Numerous imaging techniques, like magnetic resonance imaging, computed tomography scans, X-rays, etc., are further utilized to detect the underlying cause of the conditions.
The rising cases of bacterial, viral, or fungal infections, which can result in inflammation and swelling of the nasal passage, are primarily driving the paranasal sinus diseases market. In addition to this, the increasing prevalence of anatomical abnormalities that affect the production of mucus, leading to thickened secretions in the respiratory system, is also creating a positive outlook for the market. Moreover, the widespread adoption of nasal corticosteroid sprays, since they help to reduce inflammation in the nasal passages and sinuses, as well as relieve congestion and symptoms in patients, is further bolstering the market growth. Apart from this, the inflating application of immunotherapy that desensitize the immune system to specific allergens and minimize the severity of allergic reactions is acting as another significant growth-inducing factor. Additionally, the emerging popularity of functional endoscopic sinus surgery, owing to its numerous advantages, such as minimal invasiveness, faster recovery, and fewer complications compared to traditional open procedures, is expected to drive the paranasal sinus diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the paranasal sinus diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for paranasal sinus diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the paranasal sinus diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the paranasal sinus diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the paranasal sinus diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current paranasal sinus diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the paranasal sinus diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the paranasal sinus diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the paranasal sinus diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of paranasal sinus diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with paranasal sinus diseases across the seven major markets?
What is the size of the paranasal sinus diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of paranasal sinus diseases?
What will be the growth rate of patients across the seven major markets?
Paranasal Sinus Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for paranasal sinus diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the paranasal sinus diseases market?
What are the key regulatory events related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by status related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by phase related to the paranasal sinus diseases market?
What is the structure of clinical trial landscape by route of administration related to the paranasal sinus diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PARANASAL SINUS DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PARANASAL SINUS DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PARANASAL SINUS DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PARANASAL SINUS DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PARANASAL SINUS DISEASES - UNMET NEEDS
10 PARANASAL SINUS DISEASES - KEY ENDPOINTS OF TREATMENT
11 PARANASAL SINUS DISEASES - MARKETED PRODUCTS
11.1 List of Paranasal Sinus Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 FLONASE (Fluticasone Propionate) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zithromax (Azithromycin) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PARANASAL SINUS DISEASES - PIPELINE DRUGS
12.1 List of Paranasal Sinus Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 LYR-210 - Lyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tezpire (Tezepelumab) - Amgen/AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PARANASAL SINUS DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PARANASAL SINUS DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PARANASAL SINUS DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Paranasal Sinus Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Paranasal Sinus Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Paranasal Sinus Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Paranasal Sinus Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Paranasal Sinus Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Paranasal Sinus Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Paranasal Sinus Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Paranasal Sinus Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Paranasal Sinus Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Paranasal Sinus Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Paranasal Sinus Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Paranasal Sinus Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Paranasal Sinus Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Paranasal Sinus Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Paranasal Sinus Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Paranasal Sinus Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
16 PARANASAL SINUS DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PARANASAL SINUS DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PARANASAL SINUS DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PARANASAL SINUS DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PARANASAL SINUS DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PARANASAL SINUS DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PARANASAL SINUS DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PARANASAL SINUS DISEASES - UNMET NEEDS
10 PARANASAL SINUS DISEASES - KEY ENDPOINTS OF TREATMENT
11 PARANASAL SINUS DISEASES - MARKETED PRODUCTS
11.1 List of Paranasal Sinus Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 FLONASE (Fluticasone Propionate) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zithromax (Azithromycin) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PARANASAL SINUS DISEASES - PIPELINE DRUGS
12.1 List of Paranasal Sinus Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 LYR-210 - Lyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tezpire (Tezepelumab) - Amgen/AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PARANASAL SINUS DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PARANASAL SINUS DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PARANASAL SINUS DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Paranasal Sinus Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Paranasal Sinus Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Paranasal Sinus Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Paranasal Sinus Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Paranasal Sinus Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Paranasal Sinus Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Paranasal Sinus Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Paranasal Sinus Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Paranasal Sinus Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Paranasal Sinus Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Paranasal Sinus Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Paranasal Sinus Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Paranasal Sinus Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Paranasal Sinus Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Paranasal Sinus Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Paranasal Sinus Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Paranasal Sinus Diseases - Access and Reimbursement Overview
16 PARANASAL SINUS DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PARANASAL SINUS DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PARANASAL SINUS DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
